

DAFTAR PUSTAKA

1. Gurbel PA and Tantry US. Clopidogrel Resistance. *Thrombosis Research* 2007; 120 :311–321
2. Setiabudy RD. Patofisiologi Trombosis. Dalam : Hemostasis dan Trombosis. Edisi Ketiga. Editor Setiabudy RD. Penerbit FKUI 2007; 34–47
3. Cushman M. Epidemiology and Risk Factors for Venous Thrombosis. *Semin Hematol* 2007; 44(2): 62–69
4. Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. *Physiol rev* 2013; 93: 327–58
5. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WWB et al. Heart Disease and Stroke Statistics—2013 Update A Report From the American Heart Association. *Circulation* 2013; 127: e6-e245
6. Kementrian Kesehatan RI. RISKESDAS. 2013
7. Storey RF. New Developments in Antiplatelet Therapy. *European Heart Journal Supplements* 2008; 10: 30–37
8. Fox K, Cheliah R. Clopidogrel: an updated and comprehensive review. *Expert Opin. Drug Metab. Toxicol* 2007;3(4):621–631
9. Wang ZY, Chen M, Zhu LL, Zeng S, Yu LS, Xiang M, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. *Journal of Therapeutics and Clinical Risk Management* 2015;11 :449–467
10. Sangkuhl K, Klein T, Altman RB. Clopidogrel Pathway. *Journal of Pharmacogenetic Genomic* 2010. 20:7. 463-465
11. Floyd C, Passacuale G, Ferro A. Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications. *Clin Pharmacokinet* 2012; 51 (7): 429–442
12. Amin M, Chin L, Noor M, Kader M, Hay Y, Ibrahim B. The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics. *Hindawi Cardiology Research and Practice*. 2017

13. CAPRIE SC. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 1996; 348: 1329–39
14. CURE Investigator. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. *European Heart Journal* 2000;21:2033–2041
15. Krisna V, Diamond G, Kaul S. The Role of Platelet Reactivity and Genotype Testing in the Prevention of Atherothrombotic Cardiovascular Events Remains Unproven. *Circulation* 2012; 125 : 1288–1303
16. Instalasi Farmasi, RS. Dr. M.Djamil Padang. Laporan Obat Tahunan. 2016
17. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. *Circulation* 2004; 109: 3171–3175
18. Uchiyama S. Clopidogrel Resistance: Identifying and Overcoming a Barrier to Effective Antiplatelet Treatment. *Cardiovascular Therapeutics* 2011;29:100–111
19. Marcucci R, Gori AM, Paniccia R, Marcucci R, Gori AM, Pannicia R *et al.* Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. *Circulation* 2009; 119: 237–242
20. Georgios J, Dimitropoulos G, Alexopoulos D. Clopidogrel Resistance: Current Aspects and Future Directions. *Hellenic J Cardiol* 2011; 52: 236–245
21. Ray S. Clopidogrel Resistance : The Way forward. *Indian Heart Journal*. 2014; 66: 530–534
22. Aradi D, Komoschi A, Vorobcsuk A, Fuzesi M, Magyarlaki T, Horvaith I, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. *Am Heart J* 2010;160:543–51
23. Dahl K. Prevalence of clopidogrel resistance evaluated by the VASP method. *Center for Clinical Heart Research* 2011;3:210–218

24. Rizvi SK, Mohsin S, Saeed T, Ahmad S, Hussain S, Ullah MI. Frequency of Clopidogrel Resistance in Patients of Ischemic Heart Disease . *European Journal Of Cardiovascular Medicine* 2013; Vol.2:177–183
25. Paniccia R, Priora R, Alessandrello A, Abbate R. Platelet function tests: a comparative review. *Journal of Vascular Health and Risk Management* 2015;11: 133–148
26. Lenk E, Spannagl M. Platelet Function Testing – Guided Antiplatelet Therapy. *The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine* 2013; Vol.24: 3–4
27. Garabedian T, Alam S. High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. *Cardiovasc Diagn Ther* 2013;3(1):23–37
28. Jakubowski JA, Bourguet N, Boulay-Moine D, et al. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y₁₂ inhibition. *Thromb Haemost* 2012;107(2):388–395
29. Ding P, Wei Y, Chen N, Liu H. Validation of a New ELISA-Based VasodilatorAssociated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population. *Clinical and Applied Thrombosis/Hemostasis* 2017: 1–10
30. Neki NS. Clopidogrel Resistance : Current Issues. *J Enam Med Col* 2016; 6(1): 38–46
31. Gilard M, Arnoud B, Cornily J, al e. Influence of omeprazole on the antiplatelet action of clopidogrel associataed with aspirin: randomized double blind omeprazole clopidogrel aspirin (OCLA). *J AM coll Cardiol*. 2008; 51.3: 256–60
32. Cuisset T, Frere C, Quilici J, et al. Comparison Omeperazole and pantoprazole influence on a high 150 mg clopidogrel maintenance dose: PACA (proton pump inhibitor and clopidogrel association)prospective randomized study. *J Am col Cardiol* 2009;54:1149–53
33. Liau Y, Muliaty D. The Pharmacogenetics of Cytochrome P450 2C19 enzymes - Effects on Clopidogrel and Proton Pump Inhibitors Indones *Biomed J* 2014; 6(1): 33–44

34. Scott SA, Sangkukl K, Schuldiner Z, Altman RB, Klein T. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. *Journal of Pharmacogenetic Genomic*. 2012; 22: 159–165
35. Charles M, Goos D, Crossley B, Zhang K, Burkle M, Jarvis M, et al. Testing for variants in cYP2c19: population frequencies and testing experience in a clinical laboratory. *Genet Med* 2012;14(1):95–100
36. Dean L. Clopidogrel Therapy and CYP2C19 Genotype. *Medical Genetic Summaries* 2015; 102–108
37. Yang Y, Lewis JP, Hulot JS, Scott SA. The Pharmacogenetic Control of Antiplatelet Response: Candidate Genes and CYP2C19. *Expert Opin Drug Metab Toxicol* 2015 ; 11(10): 1599–1617
38. Holmes DR, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “Boxed Warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association. *Circulation* 2010; 122: 537–57
39. Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects. *Archieve Cardiovascular Disease* 2013; 650: 1–11
40. Niu X, Mao L, Huang Y, Baral S, Gao Y, Xia Y, et al. CYP2C19 Polymorphism and Clinical Outcomes among Patients of Different Races Treated with Clopidogrel: A Systematic Review and Meta-Analysis. *Journal of Huazhong Univ Sci Technol* 2015; 35: 147–156
41. Oesman F, Setiabudy RD. Fisiologi Hemostasis dan Fibrinolisis. Dalam : Hemostasis dan Trombosis. Edisi Ketiga. Editor Setiabudy RD. Penerbit FKUI. 2007: 1–15
42. Ogedegbe HO. An Overview of Hemostasis. *Laboratorymedicine* 2002; 12 (33): 949–53
43. Harrison P. Platelet function analysis. *Blood Reviews* 2005: 19; 111–123

44. Ghosal K, Bhattacharryya M. Overview of Platelet Physiology: Its Hemostatic and Nonhemostatic Role in Disease Pathogenesis. *Scientific World Journal*. 2014, Article ID 781857, 16 pages
45. Cattaneo M. P2Y₁₂ receptors: structure and function. *Journal of Thrombosis and Haemostasis* 2015;13: 10–16
46. Moheimani F, Jackson D. P2Y₁₂ receptor: platelet thrombus formation and medical Interventions. *International Journal Hematology* 2012; 96:572–587
47. Cunningham M, Nisar S, Mundell S. Molecular mechanisms of platelet P2Y₁₂ receptor regulation. *Biochem. Soc. Trans* 2013; 41: 225–230
48. Kim S, Kunapuli SP. P2Y₁₂ receptor in platelet activation. *Journal of Platelets* 2011; 22(1): 56–60
49. James K, Pula G, Poole AW. Vasodilator-stimulated phosphoprotein (VASP) is phosphorylated on Ser¹⁵⁷ by protein kinase C-dependent and -independent mechanisms in thrombin-stimulated human platelets. *Biochem. J* 2006; 393: 555–564
50. Adam V, Frank B, Joseph J. Function and regulation of Ena/VASP proteins. *Journal Trends in Cell Biology* 2003; Vol.13: 7
51. Aszodi A, Pfeifer A, Ahmad M, Glauner M, Zhou X, Ny L. et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function *The EMBO Journal* 1999; Vol.18 No.1 :37–48
52. Feher G, Feher A, Pusch G, Koltai K, Szapary L, Toth K. Clinical importance of aspirin and clopidogrel resistance *World J Cardiol* 2010 July 26; 2(7): 171–186
53. Abtan J, Silvain J, Kerneis M, Stephen A, Barthelemy O, Vignale J, et al. Identification of poor response to P2Y inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay. *Journal of Thrombosis Haemostasis* 2013; 110: 1055–1064
54. Jeong Y, Bliden K, Tantry U, Gurbel P. High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? *Journal of Thromb Haemost* 2012; 10: 487–9

55. Scott SA, Sangkukl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein T, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. *Journal of Clinical Pharmacology and Therapeutics* 2013. 94;3:317–324
56. Nakata T, Miyahara M, Nakatani K, Wada H, Tanigawa T, Komada F, et al. Relationship Between CYP2C19 Loss-of-Function Polymorphism and Platelet Reactivities With Clopidogrel Treatment in Japanese Patients Undergoing Coronary Stent Implantation. *Circ J* 2013; 77: 1436–1444
57. Gonzalez A, Moniche F, Cayuela A, Garcia J, Torrecilas F, Montaner J, et al. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting. *Eur J Vasc Endovasc Surg* 2016; 51: 175e186
58. Lee JB, Lee KA, Lee KY. Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease. *Yonsei Med J* 2011;52(5):734–738
59. Han Y, Lv H, Liu X, Dong Q, Yang X, Li S, et al. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response. *Journal of CNS Neuroscience & Therapeutics* 2015;2: 692–697
60. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytchrome P4502C19 Polymorphism in Young Patients Treated with Clopidogrel After Myocardial Infarction: a Cohort Study. *Lancet* 2009; 373 : 309–317
61. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Barrera-Ramirez C, Sabate M, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. *Thromb Res* 2005;115:101–8
62. Lepantalo A, Virtanen KS, Heikkila J, Wartiovaara U, Lassila R. Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. *European Heart Journal* 2004;25:476–83
63. Zhang S, Lai X, Li W, Xiong Z, Xu A, Huang L, et al. VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. *Journal of Thrombosis* 2014; 134(6):1272–1277

64. Park KJ, Chung HS, Kim SK, Kim HJ, Han JY, Lee SY, et al. Clinical, Pharmacokinetic, and Pharmacogenetic Determinants of Clopidogrel Resistance in Korean Patients with Acute Coronary Syndrome. *Korean Journal of Laboratory Medicine* 2011; 31: 91–94
65. Nordeen JD, Pharm D, Alden V, Patel, Robert M, Rabih G, et al. Clopidogrel Resistance by P2Y12 Platelet Function Testing in Patients Undergoing Neuroendovascular procedure. *Journal of Vascular and Interventional Neurology* 2013; 6:27–34
66. Adhitan C, Gerard N, Vasu S, Rosemary J, Shassintran H, Khrishnamoorthy R. Allele and Genotype Frequency of CYP2C19 in aTamilian Population. *British Journal of Clinical pharmacology* 2003; 56: 331–333
67. Pettersen A, Arnesen H, Opstad TB, Seljeflot I. The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. *Thrombosis Journal* 2011, 9:4
68. Brandt JT, Close SL, Ituria SJ, Payne CD, Farid NA, Ernest CS, et al. Common Polymorphism of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel. *Journal of Thrombosis and Haemostasis* 2007;5:2429–2436
69. Erlinge D, Jakubowsky D, James R, Wagner H. Clopidogrel Metaboliser Status Based on Point of Care CYP2C19 Genetic Testing in Patient with Coronary Artery Disease. *Journal of Thrombosis and Haemostasis* 2014; 115:2–9
70. Kaikata K, Ono T, Iwashita S, Nakayama N, Sato K, Horio E, et al. Impact of CYP2C19 Polimorphism on Platelet Function Test in Patient Undergoing Percutaneous Coronary Intervention. *Journal of Atherosclerosis and Thrombosis* 2014;21: 64–76